Salt Lake City, UT, 10 - 12 Jun 2024
Our team is excited to be attending Probiota Americas. This conference will feature presentations from industry thought leaders, panel discussions with Q&A and interview format sessions, and provides an opportunity to network with peers from all over the world.
If you would like to incorporate breath analysis into your microbiome research we would be eager to discuss it with you.
Dr Huw Davies has over 30 years experience working with novel technologies that enable the diagnosis and treatment of major human diseases. In his current role, Huw leads a global commercial team responsible for growing Owlstone Medical’s Breath Biopsy® collaborations and service business with leading pharmaceutical companies and academic partners to identify and deploy novel non-invasive breath biomarkers for precision medicine and disease diagnosis.
Robert Mohney’s scientific career spans >30 years in the biomedical and translational sciences, working to understand the drivers of human health and disease with the aim of disease prevention, early disease detection, and therapeutic intervention. He is the co-author of >100 peer-reviewed publications that have been cited nearly 15k times. He has extensive experience with state-of-the-art technologies for biochemical profiling, biomarker discovery, and clinical metabolomics. In his current role as Head of Clinical Biomarker Services, Rob leads a team of biologists focused on applications of volatile metabolomics profiling for identification of early disease biomarkers and precision medicine.